Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC:... Oncol Ther (2018) 6:45–58 https://doi.org/10.1007/s40487-018-0061-y ORIGINAL RESEARCH Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program . . . . Edgardo S. Santos Barry Kaplan Eli Kirshner Elisabeth F. Croft . . . Lecia V. Sequist MyDoanh Chau Jiefen Munley Geoffrey R. Oxnard Received: April 3, 2018 / Published online: May 25, 2018 The Author(s) 2018 and diagnostic methods used for T790M testing ABSTRACT in the EAP. Methods: Adult patients with EGFR T790M- Introduction: The osimertinib (AZD9291) US positive NSCLC following progression on prior Expanded Access Program (EAP) provided com- EGFR-TKI therapy (irrespective of line of ther- passionate access to osimertinib prior to US apy) were enrolled in the EAP and treated with Food and Drug Administration (FDA) approval 80 mg osimertinib once daily until dose reduc- for patients with advanced/metastatic epider- tion, discontinuation, or completion of the EAP mal growth factor receptor (EGFR) T790M-pos- following FDA approval (November 2015). Var- itive non-small cell lung cancer (NSCLC) ious testing methods were allowed for the following progression on tyrosine kinase inhi- required T790M testing. bitors (TKIs) targeting EGFR. Here, we report the Results: In total, 248 patients from 25 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Loading next page...
 
/lp/springer-journals/osimertinib-for-previously-treated-patients-with-advanced-egfr-t790m-wm00sdZmqg
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0061-y
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:45–58 https://doi.org/10.1007/s40487-018-0061-y ORIGINAL RESEARCH Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program . . . . Edgardo S. Santos Barry Kaplan Eli Kirshner Elisabeth F. Croft . . . Lecia V. Sequist MyDoanh Chau Jiefen Munley Geoffrey R. Oxnard Received: April 3, 2018 / Published online: May 25, 2018 The Author(s) 2018 and diagnostic methods used for T790M testing ABSTRACT in the EAP. Methods: Adult patients with EGFR T790M- Introduction: The osimertinib (AZD9291) US positive NSCLC following progression on prior Expanded Access Program (EAP) provided com- EGFR-TKI therapy (irrespective of line of ther- passionate access to osimertinib prior to US apy) were enrolled in the EAP and treated with Food and Drug Administration (FDA) approval 80 mg osimertinib once daily until dose reduc- for patients with advanced/metastatic epider- tion, discontinuation, or completion of the EAP mal growth factor receptor (EGFR) T790M-pos- following FDA approval (November 2015). Var- itive non-small cell lung cancer (NSCLC) ious testing methods were allowed for the following progression on tyrosine kinase inhi- required T790M testing. bitors (TKIs) targeting EGFR. Here, we report the Results: In total, 248 patients from 25

Journal

Oncology and TherapySpringer Journals

Published: May 25, 2018

References